VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
The appointment comes at a critical time for VERAXA as it seeks to advance its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats into clinical development. Willener's extensive background in corporate finance and capital markets is likely to be instrumental in securing the necessary funding and forging strategic partnerships to accelerate these efforts. His previous roles include serving as director of corporate development at Exentis Group AG, where he was later appointed CFO in 2025, leading M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This move signals VERAXA's commitment to strengthening its financial leadership as it navigates the complex landscape of oncology drug development. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. VERAXA's proprietary BiTAC(R) format represents a novel approach to engaging T cells in the fight against cancer, and the company is rapidly advancing its pipeline with a focus on quality-by-design principles.
Willener's appointment is expected to provide VERAXA with the financial expertise needed to maximize shareholder value and achieve key clinical milestones. His track record in managing large investment portfolios and leading corporate development initiatives suggests he will play a pivotal role in shaping the company's future direction. As VERAXA continues to develop its next-generation antibody-based therapeutics, the addition of a seasoned financial executive like Willener could be a decisive factor in the company's ability to translate scientific innovation into tangible patient outcomes.
The announcement also reflects a broader trend in the biotech industry, where companies are increasingly prioritizing financial leadership with deep capital markets experience to navigate funding challenges and strategic opportunities. For VERAXA, this appointment underscores its dedication to advancing its oncology pipeline and potentially delivering transformative therapies to patients in need. For more information, visit the company's newsroom at http://nnw.fm/VRXA.
